Parasitic vector-borne
diseases (VBDs) represent nearly 20% of
the global burden of infectious diseases. Moreover, the spread of
VBDs is enhanced by global travel, urbanization, and climate change.
Treatment of VBDs faces challenges due to limitations of existing
drugs, as the potential for side effects in nontarget species raises
significant environmental concerns. Consequently, considering environmental
risks early in drug development processes is critically important.
Here, we examine the environmental risk assessment process for veterinary
medicinal products in the European Union and identify major gaps in
the ecotoxicity data of these drugs. By highlighting the scarcity
of ecotoxicological data for commonly used antiparasitic drugs, we
stress the urgent need for considering the One Health concept. We
advocate for employing predictive tools and nonanimal methodologies
such as New Approach Methodologies at early stages of antiparasitic
drug research and development. Furthermore, adopting progressive approaches
to mitigate ecological risks requires the integration of nonstandard
tests that account for real-world complexities and use environmentally
relevant exposure scenarios. Such a strategy is vital for a sustainable
drug development process as it adheres to the principles of One Health,
ultimately contributing to a healthier and more sustainable world.